Last reviewed · How we verify
Whole peanut extract
Whole peanut extract is a Biologic drug developed by DBV Technologies. It is currently in Phase 1 development. Also known as: DBV712 Viaskin.
Whole peanut extract is a substance studied in clinical trials for various conditions, including Type 2 Diabetes, Cardiovascular Diseases, and Peanut Allergy. The exact mechanism of action of whole peanut extract is unknown, as per the information available on ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Whole peanut extract |
|---|---|
| Also known as | DBV712 Viaskin |
| Sponsor | DBV Technologies |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Child Health, Agriculture and Integrated Nutrition (NA)
- Using Commonly Available Food Products To Treat Food Allergy (NA)
- Role of Peanuts in Healthy Weight Gain in Athletic Individuals (NA)
- Peanut Consumption on Cognitive, Weight, and Inflammation (NA)
- Dose Response Effects of Pecan Consumption (NA)
- Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy
- Peanuts and Glycemic Control (PHASE2)
- Contrasting Ketogenic and Mediterranean Diets in Individuals With Type 2 Diabetes and Prediabetes: The Keto-Med Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Whole peanut extract CI brief — competitive landscape report
- Whole peanut extract updates RSS · CI watch RSS
- DBV Technologies portfolio CI
Frequently asked questions about Whole peanut extract
What is Whole peanut extract?
Who makes Whole peanut extract?
Is Whole peanut extract also known as anything else?
What development phase is Whole peanut extract in?
Related
- Manufacturer: DBV Technologies — full pipeline
- Also known as: DBV712 Viaskin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing